Cyclin-dependent kinase 5-mediated phosphorylation of peroxisome proliferator-activated receptor gamma at serine-273 (null)

Cyclin-dependent kinase 5 (CDK5)-mediated phosphorylation of peroxisome proliferator-activated receptor gamma (PPARγ) at serine-273 (Ser273) is a key regulatory post-translational modification implicated in metabolic diseases, particularly insulin resistance and type 2 diabetes[2][3][4]. Under pro-inflammatory and obesogenic conditions, CDK5 catalyzes phosphorylation of PPARγ at Ser273, which alters the receptor's interaction with coregulators and shifts its transcriptional program toward genes associated with insulin resistance[3][4][6]. Inhibition of this phosphorylation—by drugs, small molecules, or genetic mutation—enhances insulin sensitivity and adipocyte function, largely by promoting coactivator recruitment and reducing corepressor association[1][3]. This pathway is considered a promising therapeutic target for metabolic disorders, with the goal of achieving insulin sensitization independent of classic PPARγ agonism and its associated side effects[2][4]. Several experimental drugs and natural metabolites (e.g., 3-hydroxybutyrate) have been shown to block this phosphorylation, improving metabolic parameters in models of obesity and diabetes[1][4]. However, the clinical relevance and translatability of this mechanism remain under investigation, and standard biomarkers such as phosphorylated PPARγ (Ser273) and adipokines like adiponectin may reflect target engagement and therapeutic efficacy[4][6].

Other names

CDK5-mediated PPARγ Ser273 phosphorylationPPARγ Ser273 phosphorylationPPARγ S273 phosphorylationObesity-linked PPARγ phosphorylationCDK5/PPARγ Ser-273 signaling

Inhibition of PPARγ Ser273 phosphorylation enhances insulin sensitivity, Blockade of CDK5 activity reduces insulin resistance, PPARγ modulation alters coactivator/corepressor recruitment, Modulation of gene expression in adipocytes